Rare but clinically important salivary gland-type tumor of the lung : A review
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Salivary gland-type tumor (SGT) of the lung, which arises from the bronchial glands of the tracheobronchial tree, was first recognized in the 1950s. SGT represents less than 1% of all lung tumors and is generally reported to have a good prognosis. Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) are the two most common subtypes, comprising more than 90% of all SGTs. The reported 5-year survival rate of patients with SGT is 63.4%. Because this type of tumor develops in major bronchi, patients with SGT commonly present with symptoms of bronchial obstruction, including dyspnea, shortness of breath, wheezing, and coughing; thus, the tumor is usually identified at an early stage. Most patients are treated by lobectomy and pneumonectomy, but bronchoplasty or tracheoplasty is often needed to preserve respiratory function. Lymphadenectomy in the surgical resection of SGT is recommended, given that clinical benefit from lymphadenectomy has been reported in patients with MEC. For advanced tumors, appropriate therapy should be considered according to the subtype because of the varying clinicopathologic features. MEC, but not ACC, is less likely to be treated with radiation therapy because of its low response rate. Although previous researchers have learned much from studying SGT over the years, the diagnosis and treatment of SGT remains a complex and challenging problem for thoracic surgeons. In this article, we review the diagnosis, prognosis, and treatment (surgery, chemotherapy, and radiotherapy) of SGT, mainly focusing on MEC and ACC. We also summarize reports of adjuvant and definitive radiation therapy for ACC in the literature.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Japanese journal of clinical oncology - 54(2024), 2 vom: 07. Feb., Seite 121-128 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takamori, Shinkichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 08.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jjco/hyad154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364437545 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364437545 | ||
| 003 | DE-627 | ||
| 005 | 20240208231917.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jjco/hyad154 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM364437545 | ||
| 035 | |a (NLM)37952098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takamori, Shinkichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rare but clinically important salivary gland-type tumor of the lung |b A review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Salivary gland-type tumor (SGT) of the lung, which arises from the bronchial glands of the tracheobronchial tree, was first recognized in the 1950s. SGT represents less than 1% of all lung tumors and is generally reported to have a good prognosis. Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) are the two most common subtypes, comprising more than 90% of all SGTs. The reported 5-year survival rate of patients with SGT is 63.4%. Because this type of tumor develops in major bronchi, patients with SGT commonly present with symptoms of bronchial obstruction, including dyspnea, shortness of breath, wheezing, and coughing; thus, the tumor is usually identified at an early stage. Most patients are treated by lobectomy and pneumonectomy, but bronchoplasty or tracheoplasty is often needed to preserve respiratory function. Lymphadenectomy in the surgical resection of SGT is recommended, given that clinical benefit from lymphadenectomy has been reported in patients with MEC. For advanced tumors, appropriate therapy should be considered according to the subtype because of the varying clinicopathologic features. MEC, but not ACC, is less likely to be treated with radiation therapy because of its low response rate. Although previous researchers have learned much from studying SGT over the years, the diagnosis and treatment of SGT remains a complex and challenging problem for thoracic surgeons. In this article, we review the diagnosis, prognosis, and treatment (surgery, chemotherapy, and radiotherapy) of SGT, mainly focusing on MEC and ACC. We also summarize reports of adjuvant and definitive radiation therapy for ACC in the literature | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a non-small cell lung cancersalivary gland-type tumormucoepidermoid carcinomaadenoid cystic carcinoma | |
| 700 | 1 | |a Yatabe, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Osoegawa, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Aokage, Keiju |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshioka, Hiroshige |e verfasserin |4 aut | |
| 700 | 1 | |a Miyoshi, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Mimae, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Endo, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Hattori, Aritoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yotsukura, Masaya |e verfasserin |4 aut | |
| 700 | 1 | |a Isaka, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Isaka, Mitsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Maniwa, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakajima, Ryu |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Shun-Ichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Japanese journal of clinical oncology |d 1983 |g 54(2024), 2 vom: 07. Feb., Seite 121-128 |w (DE-627)NLM012592978 |x 1465-3621 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:2 |g day:07 |g month:02 |g pages:121-128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jjco/hyad154 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 2 |b 07 |c 02 |h 121-128 | ||